Evidence map›Paper›PMID 38139966›Full record

ArticlePolymers2023

Development of an Electroactive and Thermo-Reversible Diels-Alder Epoxy Nanocomposite Doped with Carbon Nanotubes.

Isaac Lorero, Álvaro Rodríguez, Mónica Campo, Silvia G Prolongo

Abstract read
In one paragraph

Article in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Isaac LoreroMaterials Science and Engineering Area, Rey Juan Carlos University, C/Tulipán s/n, 28933 Móstoles, Madrid, Spain.ORCID 0000-0001-9426-9665
Álvaro RodríguezMaterials Science and Engineering Area, Rey Juan Carlos University, C/Tulipán s/n, 28933 Móstoles, Madrid, Spain.
Mónica CampoMaterials Science and Engineering Area, Rey Juan Carlos University, C/Tulipán s/n, 28933 Móstoles, Madrid, Spain.ORCID 0000-0002-4333-5236
Silvia G ProlongoMaterials Science and Engineering Area, Rey Juan Carlos University, C/Tulipán s/n, 28933 Móstoles, Madrid, Spain.ORCID 0000-0002-4438-6123

Funding

Agencia Estatal de Investigación PID2022-138496OB-I00Agencia Estatal de Investigación TED2021-131102B-C21
6 · The paper itself

Abstract

The manufacturing of Diels-Alder (D-A) crosslinked epoxy nanocomposites is an emerging field with several challenges to overcome: the synthesis is complex due to side reactions, the mechanical properties are hindered by the brittleness of these bonds, and the content of carbon nanotubes (CNT) added to achieve electroactivity is much higher than the percolation thresholds of other conventional resins. In this work, we develop nanocomposites with different D-A crosslinking ratios (0, 0.6, and 1.0) and CNT contents (0.1, 0.3, 0.5, 0.7, and 0.9 wt.%), achieving a simplified route and avoiding the use of solvents and side reactions by selecting a two-step curing method (100 °C-6 h + 60 °C-12 h) that generates the thermo-reversible resins. These reversible nanocomposites show ohmic behavior and effective Joule heating, reaching the dissociation temperatures of the D-A bonds. The fully reversible nanocomposites (ratio 1.0) present more homogeneous CNT dispersion compared to the partially reversible nanocomposites (ratio 0.6), showing higher electrical conductivity, as well as higher brittleness. For this study, the nanocomposite with a partially reversible matrix (ratio 0.6) doped with 0.7 CNT wt.% was selected to allow us to study its new smart functionalities and performance due to its reversible network by analyzing self-healing and thermoforming.

Indexed as

CANDiels–Alder thermosetelectroactive polymernanocompositesshape memory

Identifiers

PMID38139966
PMCPMC10747943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.